Cierra raises $21m for catheter-based heart-treatment to reduce migraine:
This article was originally published in Clinica
Cierra, which is developing a catheter system to treat the heart defect, patent foramen ovale (PFO), has raised $21m from venture investors led by Delphi Ventures. A PFO is a valve-like opening between the left and right atria, which studies have linked to migraine headaches. The Redwood, California company will use the funds to begin US clinical trials and commercialise its PFX non-implant-based system to close the hole with a view to reducing migraine in sufferers. Other companies offering implant-based closure of PFO include NMT Medical (Boston, Massachusetts) and AGA Medical (Golden Valley, Minnesota).
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.